184 completed. 184 Phase 1, 38 Phase 2.
By phase and status
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Trials (filtered) newest first · largest first
All 184 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infection Phase 1 Completed 12 2026-03-10 2026-08-21 A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults AVX70371, Placebo - Chronic Hepatitis b Phase 1 Completed 16 2025-05-06 2026-10-08 A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients HH-006, 0.9% normal saline - Chronic Hepatitis B Virus Infection Phase 1 Completed 36 2024-12-20 2026-04-07 A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B Placebo, BW-20507 - Chronic Hepatitis B Phase 1 Completed 32 2024-06-24 2026-07-31 A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection ABI-4334, Placebo - Chronic Hepatitis B Phase 1 Completed 20 2024-06-04 2025-07-23 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B CB06-036, Placebo - Chronic Hepatitis b Phase 1 Completed 30 2024-04-22 2025-05-21 A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate HEPLISAV B; TherVacB, TherVacB - Chronic Hepatitis B Phase 1 Completed 26 2024-01-23 2026-06-04 Relative Bioavailability Study of HR19042 in Healthy Subjects HR19042 Capsule, Tarpeyo®, Budenofalk® - Primary IgA Nephropathy; Autoimmune Hepatitis Phase 1 Completed 18 2023-12-27 2025-04-22 Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy VRON-0200-AdC6, VRON-0200-AdC7, VIR-2218 - Chronic Hepatitis B Phase 1 Completed 35 2023-09-26 2026-08-19 Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. AB-101, Placebo, Nucleos(t)ide Analogue - Chronic Hepatitis b Phase 1 Completed 128 2023-08-30 2026-04-13 A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients AHB-137 injection, Placebo - Hepatitis B, Chronic Phase 1 / Phase 2 Completed 129 2023-08-03 2026-05-07 Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients With Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity HT-102, Placebo - Chronic Hepatitis B Phase 1 Completed 56 2023-06-12 2026-11-02 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic Phase 1 / Phase 2 Completed 33 2023-05-10 2026-02-09 Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B GS-2829, GS-6779, Placebo - Chronic Hepatitis B Phase 1 Completed 83 2023-04-03 2026-01-23 A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B AHB-137 injection, Placebo - Chronic Hepatitis B Phase 1 Completed 64 2023-02-28 2025-02-14 This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity HT-101, Placebo - Chronic Hepatitis b Phase 1 Completed 82 2022-11-22 2026-11-02 A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects ABI-4334 Tablet, ABI-4334 Placebo - Chronic Hepatitis B Phase 1 Completed 54 2022-11-11 2023-09-13 Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects 162, Placebo - Chronic Hepatitis B Phase 1 Completed 20 2022-09-30 2023-11-27 The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection P1101 + Nivolumab + Entecavir - Chronic Hepatitis B Infection, Chronic Hepatitis D Infection Phase 1 Completed 20 2022-08-17 2026-06-10 A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection ABI-H3733, Placebo - Chronic Hepatitis B Phase 1 Completed 31 2022-08-07 2023-06-29
Showing 20 of 184. Sign in to see all of them.
Narrower conditions Hepatitis C, Chronic (88) · Hepatitis B, Chronic (87) · Hepatitis C (31) · Hepatitis B (17) · Hepatitis (9) · Liver Diseases (6) · Virus Diseases (5) · Hepatitis, Autoimmune (3) · Bronchiolitis Obliterans Syndrome (2) · DNA Virus Infections (2) · Hepatitis, Viral, Human (2) · Infections (2) · Acquired Immunodeficiency Syndrome (1) · Cholangitis, Sclerosing (1)
Broader conditions Digestive System Diseases (184) · Pathologic Processes (182) · Pathological Conditions, Signs and Symptoms (182) · Disease Attributes (181) · Chronic Disease (180) · Blood-Borne Infections (179) · Communicable Diseases (179) · Liver Diseases (178) · Hepatitis, Viral, Human (177) · Infections (177) · Hepatitis (175) · Virus Diseases (174) · RNA Virus Infections (92) · Flaviviridae Infections (91)
Interventions Ribavirin (13) · entecavir (12) · peginterferon alfa-2a (12) · Tenofovir (8) · Ritonavir (6) · Midazolam (4) · telaprevir (4) · faldaprevir (3) · samatasvir (3) · tenofovir alafenamide (3) · BID protein, human (2) · Drug and Narcotic Control (2) · GSK2878175 (2) · IDX184 (2) · Itraconazole (2)
Sponsors Merck Sharp & Dohme LLC (13) · Assembly Biosciences (10) · Hoffmann-La Roche (10) · Sunshine Lake Pharma Co., Ltd. (10) · Bristol-Myers Squibb (8) · Boehringer Ingelheim (7) · Gilead Sciences (6) · Alios Biopharma Inc. (4) · GlaxoSmithKline (4) · Enyo Pharma (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Pfizer (3) · Tanabe Pharma Corporation (3) · Vertex Pharmaceuticals Incorporated (3) · Vir Biotechnology, Inc. (3)
Countries United States (54) · China (38) · New Zealand (27) · South Korea (19) · Hong Kong (16) · Taiwan (16) · France (15) · Australia (14) · Germany (12) · Moldova (11) · United Kingdom (11) · Canada (9) · Puerto Rico (9) · Singapore (9) · Belgium (8)
Top investigators Yanhua Ding, Doctor (7) · Fumitaka Suzuki, MD (2) · Junqi Niu (2) · Mamun Al-Mahtab, MD (2) · Nathaniel Brown, M.D. (2) · Piyush Patel, M.D. (2) · Yanhua Ding (2)
Results publications PMID 27257978 , PMID 30625297 , PMID 16310901 , PMID 20090916 , PMID 20091678 , PMID 20938912 , PMID 20951424 , PMID 21145839 , PMID 21354234 , PMID 21488067 , PMID 21699798 , PMID 22239508 , PMID 22414766 , PMID 22425702 , PMID 23070151 , PMID 23190247 , PMID 23396509 , PMID 23490393 , PMID 23774433 , PMID 23872824 , PMID 23877706 , PMID 24145880 , PMID 24148552 , PMID 24295986 , PMID 24394187 , PMID 24434503 , PMID 24555998 , PMID 24733462 , PMID 25385099 , PMID 25406369 , PMID 25456558 , PMID 25801562 , PMID 26183611 , PMID 26257082 , PMID 26621580 , PMID 26733671 , PMID 27353271 , PMID 28704412 , PMID 29301580 , PMID 29638206 , PMID 29736243 , PMID 30088198 , PMID 30325939 , PMID 30350297 , PMID 30680407 , PMID 31267367 , PMID 31323705 , PMID 31570394 , PMID 31711752 , PMID 31868916
NIH funding 2017 (3) , 2008 (2) , 2009 (2) , 2016 (2) , 2015 (1) , 2019 (1) , 2025 (1) , R01DK090794 (1) , R21AT003892 (1) , R21HD101996 (1) , R34HL109334 (1)